Inclusion Criteria:

- Confirmed diagnosis of intrahepatic carcinoma. The histopathology confirmation
criterion may be waived in patients with a radiographically identifiable liver mass,
known laboratory or clinical risk factors for cancer or elevated tumor markers such
as Alpha-fetoprotein assay (AFP) (clinical diagnosis).

- The cancer must be unresectable.

- Eastern Cooperative Oncology Group (ECOG) Performance Status Score 0 - 2

- Age ≥ 18 years.

- Able to comprehend and read the study information sheet in accordance with
institutional and federal guidelines.

Exclusion Criteria:

- Any pre-treatment laboratory findings within 15 days of treatment demonstrating:

- Absolute granulocyte count ≤ 1,500/ul

- Platelet count ≤ 75,000/μl

- Serum creatinine ≥ 2.0 mg/dl

- Serum bilirubin ≥ 2.0 mg/dl

- Any of the following contraindications to angiography and selective visceral
catheterization:

- History of severe allergy or intolerance to any contrast media, narcotics,
sedatives, or atropine

- Bleeding diathesis, not correctable by usual forms of therapy

- Severe peripheral vascular disease that would preclude catheterization.

- Portal hypertension with portal venous shunt away from the liver.

- Evidence of potential delivery of greater than 16.5 millicurie (mCi) (30 Gy absorbed
dose) of radiation to the lungs on either: 1) first TheraSphere administration; or 2)
cumulative delivery of radiation to the lungs > 30 Gy over multiple treatments.

- Evidence of any detectable Tc-99m MAA flow to the stomach or duodenum, after
application of established angiographic techniques to stop such flow.

- Significant extrahepatic disease representing an imminent life-threatening outcome.

- Severe liver dysfunction or pulmonary insufficiency.

- Active uncontrolled infection.

- Significant underlying medical or psychiatric illness.

- Pregnant women may not participate.